N-(5-benzamido-2-phenyl-1,2,4-triazol-3-yl)-3-nitrobenzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(5-benzamido-2-phenyl-1,2,4-triazol-3-yl)-3-nitrobenzamide
• 化学式: C22H16N6O4
• 分子量: 428.4
• InChiKey: MZARAQUSHANMQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
  申请人：An2H Discovery Limited

  公开号：US20200172497A1

  公开（公告）日：2020-06-04

  The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R 1 , R 2 , R 3 , M 1 , M 2 , M 3 , L 1 , L 2 , and L 3 are as defined herein.

  本公开涉及公式（I）和公式（II）的不对称三唑苯甲酰胺化合物，以及其制药组合物和调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或减少与激活Parkin连接酶相关的疾病或症状的方法。R1、R2、R3、M1、M2、M3、L1、L2和L3如本文所定义。
• Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
  申请人：NysnoBio Ireland DAC

  公开号：US10889553B2

  公开（公告）日：2021-01-12

  The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

  本公开涉及式(I)和式(II)的不对称三唑苯甲酰胺化合物、其药物组合物以及调节或激活Parkin连接酶的方法。本公开还涉及治疗和/或降低与激活Parkin连接酶有关的疾病或病症发病率的方法。R1、R2、R3、M1、M2、M3、L1、L2 和 L3 如本文所定义。
• TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
  申请人：An2H Discovery Limited

  公开号：US20180118697A1

  公开（公告）日：2018-05-03

  The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R 1 , R 2 , R 3 , M 1 , M 2 , M 3 , L 1 , L 2 , and L 3 are as defined herein.
• METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION
  申请人：NysnoBio Ireland DAC

  公开号：US20210244712A1

  公开（公告）日：2021-08-12

  The present disclosure relates to methods of treating cancer comprising administering Parkin ligase activator or a pharmaceutically acceptable salt thereof to a subject who has a mutant form of a protein in the Rb checkpoint pathway. The Parkin ligase activator includes triazole compounds, such as compounds of formula (I), and pharmaceutically acceptable salts thereof as disclosed herein. R 1 , R 2 , R 3 , M 1 , M 2 , M 3 , L 1 , L 2 , and L 3 are as defined herein.